(P035) The Prognostic Value of Pretreatment Peripheral Blood Neutrophil-to-Lymphocyte Ratio in Patients With Soft Tissue Sarcoma

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

While our results do not demonstrate high neutrophil-to-lymphocyte ratio to be an independent risk factor for worsened clinical outcomes, they do show high neutrophil-to-lymphocyte ratio to have statistically and clinically significant predictive value for RFS and OS in patients with recently diagnosed soft tissue sarcoma.

William H. Smith, Vishal Gupta, MD, Elizabeth G. Demicco, MD, Ilya Iofin, MD, Robert G. Maki, MD, PhD; Icahn School of Medicine at Mount Sinai

PURPOSES/OBJECTIVES: There has been growing interest in the prognostic value of peripheral blood neutrophil-to-lymphocyte ratio (NLR) in solid malignancies, but there are limited data on sarcomas. In this study, we sought to elucidate the relationship between pretreatment NLR and relapse-free survival (RFS) and overall survival (OS) in patients with recently diagnosed soft tissue sarcoma (STS).

METHODS: We queried our institutional pathology database for patients diagnosed with STS between January 2009 and December 2013. Included patients had pretreatment peripheral blood complete blood count (CBC) available within 1 month of surgery and prior to chemotherapy/radiation therapy (RT). Patients with rhabdomyosarcoma and solitary fibrous tumor histology were excluded. Patients were categorized into high- NLR (NLR ≥ 5) and low-NLR (NLR  < 5) groups based on CBC. Clinical patient data were obtained, and OS and RFS were compared using Kaplan-Meier analysis and Cox proportional hazards analysis.

RESULTS: A total of 122 patients met the inclusion criteria for our study. Among these patients, 26 (21%) were included in the high-NLR group, and 88 (72%) formed the low-NLR group. Eight (7%) had CBC without differential and were included solely for multivariate analysis. After a median follow-up of 19 months, high pretreatment NLR was associated with increased risk of mortality (hazard ratio [HR], 2.499 [95% CI, 1.193–5.232]) and increased risk of recurrence (HR, 2.688 [95% CI, 1.093–6.611]). On multivariate analysis with Cox proportional hazards modeling, this effect was not found to be significant after correction for age, stage, and histologic subtype.

DISCUSSION: While our results do not demonstrate high NLR to be an independent risk factor for worsened clinical outcomes, they do show high NLR to have statistically and clinically significant predictive value for RFS and OS in patients with recently diagnosed STS. Longer follow-up and more patients are needed to validate these findings.

Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content